TIBET PHARMA(SH:600211) Xin Lang Zheng Quan·2025-09-19 06:02Company Overview - Tibet Pharmaceutical Co., Ltd. is located in Lhasa Economic and Technological Development Zone, Tibet, and was established on July 14, 1999, with its listing date on July 21, 1999. The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales and 0.20% from other sources [1]. Stock Performance - As of September 19, the stock price of Tibet Pharmaceutical fell by 2.00% to 51.34 CNY per share, with a trading volume of 272 million CNY and a turnover rate of 1.62%. The total market capitalization is 16.548 billion CNY [1]. - Year-to-date, the stock has increased by 46.40%, but it has decreased by 9.02% over the last five trading days. In the last 20 days, the stock rose by 13.69%, and over the past 60 days, it increased by 43.49% [1]. Financial Performance - For the first half of 2025, Tibet Pharmaceutical reported a revenue of 1.651 billion CNY, representing a year-on-year growth of 2.23%. However, the net profit attributable to shareholders decreased by 8.96% to 567 million CNY [2]. Shareholder Information - As of June 30, 2025, the number of shareholders for Tibet Pharmaceutical was 45,200, a decrease of 8.08% from the previous period. The average number of circulating shares per person increased by 8.79% to 7,132 shares [2]. - The company has distributed a total of 2.258 billion CNY in dividends since its A-share listing, with 1.580 billion CNY distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 2.5902 million shares, a decrease of 1.6084 million shares from the previous period. Huaxia Industry Prosperity Mixed Fund (003567) was the tenth-largest circulating shareholder, maintaining its holding of 1.9036 million shares [3].